About: wd:Q28200530

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: wd:Q28200530 Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article (publication date: October 2006)

Attributes	Values
rdf:type	Item
description	article scientifique publié en 2006 (fr) artículu científicu espublizáu en 2006 (ast) vědecký článek publikovaný v roce 2006 (cs) 2006 թվականի հոտեմբերին հրատարակված գիտական հոդված (hy) 2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած (hyw) наукова стаття, опублікована в жовтні 2006 (uk) vedecký článok (publikovaný 2006-10) (sk) wetenschappelijk artikel (gepubliceerd in 2006-10) (nl) مقالة علمية (نشرت في أكتوبر 2006) (ar) scientific article (publication date: October 2006) (en) im Oktober 2006 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q28200530-9DBE8B46-ECC2-4FB3-83E3-991CBB9446F1
publication date	2006-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q28200530-5A439873-1317-4158-A32B-6F1CA1EFA869
language of work or name	English
author name string	wds:Q28200530-2CB5EC09-21BB-49FF-936F-DDB94FFC182D wds:Q28200530-CD9830FC-774B-46A7-9E89-E099A6DF687B wds:Q28200530-CE2D3A76-8305-49A5-A6F5-F55065E3C4AA
author name string	C Michael Gibson Kenneth J Winters Jeffrey W Warmke
rdfs:label	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial (nl)
skos:prefLabel	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial (nl)
name	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial (nl)
author	wds:Q28200530-22275849-B541-44F9-BF9E-01AE34EE3F3F wds:Q28200530-526D6AB0-D25D-4A5F-850A-F84FEDA6991F wds:Q28200530-5726BBD1-EF74-421A-B7B0-027F470F9247 wds:Q28200530-770E0820-79A0-43FA-8055-231FB8CB1FFC wds:Q28200530-870F5586-B7E9-44A4-A358-98C9C1B59859 wds:Q28200530-8B033FA5-9B31-4A2C-966D-4F1862AC93CA wds:Q28200530-CFD70F82-7C04-4828-AD3C-7A42801E71DB
author	Eugene Braunwald Carolyn F McCabe Elliott M Antman Stephen D Wiviott Gilles Montalescot Jeffrey R Riesmeyer Govinda Weerakkody
title	wds:Q28200530-28EB0FBB-8CC2-49B6-B13D-AF73A6AA634E
title	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (en)
page(s)	wds:Q28200530-8E9B5893-A0A8-4A0E-974D-895A72A6717E
page(s)	627-35
instance of	wds:Q28200530-4F93A00F-0AA2-4BDD-945B-24B8C37C644C
instance of	scholarly article
main subject	wds:Q28200530-056D3622-B3D6-418C-9A75-66820B88A095 wds:Q28200530-7366868F-EB69-4F59-B0DA-5CF63DDD466D wds:Q28200530-7FCB016F-1BEB-4F55-BCD4-A206C3DAD82D wds:Q28200530-9E1D8133-3C28-4ED8-ACA2-16695FCA73FF
main subject	acute coronary syndrome wd:Q410237 thrombolysis Patients
PubMed ID	wds:Q28200530-694D6370-3795-491B-9CE1-C1FAE8E5D46F
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16996826
PubMed ID	16996826
published in	wds:Q28200530-69C22A29-A588-4F84-904B-D7C23760ED85
published in	American Heart Journal
issue	wds:Q28200530-A3C2E7C0-1F9F-4136-B455-070625571AF7
volume	wds:Q28200530-5312A63F-3C25-4908-8BFE-4CF15E7BC746
issue	4
volume	152
DOI	wds:Q28200530-ABF5FF03-2FA4-45FA-9AF3-CFA438C603FD
DOI	http://dx.doi.org/10.1016/J.AHJ.2006.04.012
DOI	10.1016/J.AHJ.2006.04.012
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q28200530
is cites work of	Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. Age related issues in reperfusion of myocardial infarction Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention Prasugrel: a critical comparison with clopidogrel. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects Subgroup analyses of clinical effectiveness to support health technology assessments Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting Thrombin generation in hemorrhage control and vascular occlusion Management standards for stable coronary artery disease in India Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes Clopidogrel hypersensitivity: clinical challenges and options for management Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software